Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07531043 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of FID 123472 Ophthalmic Solution for Ocular Redness in Adults
A Phase 3 study, sponsored by Alcon Research.
- Not yet
- Registry status
- Phase 3
- Development phase
- 230
- Enrollment target
NCT07531043 is a Phase 3 study that has not yet begun recruiting, run by Alcon Research. The registered enrollment target is 230 participants.
The verdict
NCT07531043, a Phase 3 study, has not yet begun recruiting, sponsored by Alcon Research.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 230 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of an investigational ophthalmic solution in adults with ocular redness due to minor eye irritations.
Interventions
- DRUG Vehicle
- DRUG Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2026-10 |
| Est. Completion | 2027-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07531043
The ClinicalTrials.gov registry entry for NCT07531043 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 230 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT07531043 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07531043 about?
NCT07531043 is a clinical study titled "Efficacy and Safety of FID 123472 Ophthalmic Solution for Ocular Redness in Adults". The purpose of this study is to evaluate the efficacy and safety of an investigational ophthalmic solution in adults with ocular redness due to minor eye irritations.
What is the current status of trial NCT07531043?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 230 participants. The study started on 2026-10. Estimated completion is 2027-02.
What interventions are being tested in trial NCT07531043?
The interventions under investigation include: Vehicle (DRUG), Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free (DRUG).
Who is sponsoring clinical trial NCT07531043?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.